Beijing-based biopharmaceutical company InnoCare Pharma Tech Co. is planning a Hong Kong stock market listing as soon as this year.
InnoCare is expected to seek around $250 million from the initial public offering.
The company, with investors including 3H Health Investment, Jianxin Capital and Loyal Valley Capital, has been interviewing potential advisers on the deal.
The company, which has raised a combined $215 million from two funding rounds last year, was valued at about $800 million in its latest financing.